Pancreatic ductal adenocarcinoma (PDAC) is more prevalent in older patients, but early-onset cases (<55 years) may be a distinct genetic subpopulation. Differential expression of CDKN2A and transcription factor FOXC2 were found in early-onset cases. This finding opens the door to investigating additional features that distinguish PDAC tumors in this age group.
Bibliographical noteFunding Information:
E. Lou reports research grants from the American Association for Cancer Research (2019 AACR-Novocure Tumor-Treating Fields Research Grant) and the Minnesota Ovarian Cancer Alliance; honorarium and travel expenses for a research talk at GlaxoSmithKline (2016); honoraria and travel expenses for lab-based research talks, and equipment for laboratory-based research from Novocure (2018–20); consultant, Nomocan Pharmaceuticals (unpaid); scientific advisory board member, Minnetronix, LLC (2018–present; unpaid); consultant and speaker honorarium, Boston Scientific US (2019); institutional principal investigator for clinical trials sponsored by Celgene, Novocure, Intima Biosciences, and the NCI; and University of Minnesota membership in the Caris Life Sciences Precision Oncology Alliance (unpaid).
© 2020 American Association for Cancer Research.
PubMed: MeSH publication types
- Journal Article
- Research Support, Non-U.S. Gov't